At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the October 2026 edition.

The IMF team of medical editors has provided overviews of key studies. We encourage you to visit the original journal articles for full details and to deepen your understanding. Check the IMF Newsroom monthly for updates like this one.

In the Journals (Key Myeloma Research in October 2026)

"Apparent diffusion coefficient histogram parameters of the whole tumor based on whole-body magnetic resonance imaging can better characterize the tumor burden of multiple myeloma and predict survival prognosis"

Source

Dong H, Qi Q, Ji X, Gao S, Zhang K, Liu S, Song Z, Huang W, Xia S. Apparent diffusion coefficient histogram parameters of the whole tumor based on whole-body magnetic resonance imaging can better characterize the tumor burden of multiple myeloma and predict survival prognosis. Quant Imaging Med Surg. 2026 Oct 1;16(10):782. doi: 10.21037/qims-2026-0524. Epub 2026 Sep 11. 

Overview

Researchers examined whether whole-body MRI measurements of water movement across all tumor sites could better estimate disease burden and help predict survival in newly diagnosed myeloma. In this retrospective study of 95 patients, whole-tumor measurements correlated with bone marrow plasma cell levels, and several imaging measures were associated with survival. The approach needs further validation before routine use for prognosis. 

"Targeting metabolic reprogramming and epigenetic remodeling: a novel strategy to reshape the immune microenvironment in multiple myeloma"

Source

Mingjie Wang, Le Wang, Jiapei Yuan, Targeting metabolic reprogramming and epigenetic remodeling: a novel strategy to reshape the immune microenvironment in multiple myeloma, International Immunopharmacology, Volume 186, 2026, 117143, ISSN 1567-5769, https://doi.org/10.1016/j.intimp.2026.117143. October 1, 2026. 

Overview

This review explains how changes in cancer-cell metabolism interact with changes in gene regulation to help myeloma evade the immune system. The authors discuss whether targeting these connected processes could improve responses to immunotherapy. The proposed combinations provide a framework for future research rather than an established treatment approach. 

"Immunoglobulin A Subtype and Survival After Upfront Autologous Stem Cell Transplantation in Multiple Myeloma: A Real-World Cohort from the Bortezomib Era"

Source

Güllü Koca, T., Koca, N., Hunutlu, F . Ç., Yanık, A. M., Çubukçu, S., Yılmaz, R., Ersal, T., Gürsoy, V ., Pınar, İ. E., Özkocaman, V ., & Özkalemkaş, F . (2026). Immunoglobulin A Subtype and Survival After Upfront Autologous Stem Cell Transplantation in Multiple Myeloma: A Real-World Cohort from the Bortezomib Era. Cancers, 18(19), 3178. https://doi.org/10.3390/cancers18193178 October 1, 2026. 

Overview

Researchers compared outcomes after an initial autologous stem cell transplant in 196 patients with IgA or IgG myeloma. IgA myeloma was associated with a shorter time before progression, while the size of its association with overall survival was uncertain. Incomplete chromosome-risk data limit interpretation, so the findings require confirmation in more fully characterized patient groups. 

"The interval and factors associated with time from loss of complete response to relapse in newly diagnosed multiple myeloma after autologous stem cell transplantation"

Source

Bi, J., Liu, Y ., Zhang, Y . et al. The interval and factors associated with time from loss of complete response to relapse in newly diagnosed multiple myeloma after autologous stem cell transplantation. Discov Onc (2026). 

 https://doi.org/10.1007/s12672-026-06054-1 October 1, 2026. 

Overview

Researchers reviewed 47 patients who lost a complete response after autologous stem cell transplantation to determine how long it took for biochemical or clinical relapse to follow. The median interval was eight months, with substantial variation. Earlier loss of response and more advanced disease stage were associated with faster relapse in exploratory analyses, supporting further study of individualized monitoring. 

"Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of earlystage and relapsed multiple myeloma"

Source

Williams CM, Noll JE, Harnas D, Parkinson HB, Hewett DR, Zannettino AC, Vandyke K, Cox TR, Panagopoulos V . Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of earlystage and relapsed multiple myeloma. Haematologica 2026; 111(10):3398-3411; https://doi.org/10.3324/haematol.2025.300383. October 1, 2026. 

Overview

This preclinical study tested whether blocking myeloperoxidase, an enzyme that influences the bone marrow environment, could slow myeloma or delay its return. In mouse models, AZD5904 reduced early tumor growth and delayed relapse when given after bortezomib, but did not help established disease when started alone. These results support further investigation of maintenance treatment, with benefit in patients still unproven. 

"Survivorship and Health Maintenance in Patients With Multiple Myeloma: A Nurse-Led Survivorship Care Framework"

Source

Bellerive, C., Miceli, T., Brigle, K., Faiman, B., & Steinbach, M. (2026). Survivorship and Health Maintenance in Patients With Multiple Myeloma: A Nurse-Led Survivorship Care Framework. Clinical Journal of Oncology Nursing, 30(5), E87-E96. https://doi.org/10.1188/26.CJON.E87-E96 October 2026. 

Overview

This article addresses the need for nurse-led survivorship care as people with myeloma live longer. Its focus extends beyond controlling the cancer to treatment side effects, other health conditions, emotional distress, and unequal access to care. The supplied abstract introduces the rationale for a comprehensive survivorship framework but does not provide results evaluating its effectiveness. 

"Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool"

Source

Kevin Charles Miller, Teng Fei, Ruben J. Faustino Ramos, Francesca Castro, Ana Gradissimo, Torin Block, Issam Hamadeh, Kylee H. Maclachlan, Malin L. Hultcrantz, Hani Hassoun, Sham Mailankody, Sridevi Rajeeve, Francesco Maura, Maximilian Merz, Hamza Hashmi, Ross Firestone, Eric Jurgens, Gunjan L. Shah, Michael Scordo, Heather J. Landau, Sergio A. Giralt, Neha Korde, Matthew J. Pianko, Saad Z. Usmani, Jonathan U. Peled, Urvi A. Shah, Alexander M. Lesokhin; Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool. Clin Cancer Res 1 October 2026; 32 (19): 4474-4488. https://doi.org/10.1158/1078-0432.CCR-26-0752 

Overview

Researchers investigated whether changes in gut bacteria and bile acids contribute to diarrhea during lenalidomide maintenance. Samples from two prospective trials linked diarrhea to reduced bacterial diversity and altered bile acid processing. Differences present before treatment also suggested possible risk markers. The findings support research into microbiome-based approaches but do not establish that changing gut bacteria prevents diarrhea. 

"Racial Disparities in the Management of Myeloma Bone Disease: A Retrospective Cohort Study"

Source

Ruxandra M. Irimia et al. Racial Disparities in the Management of Myeloma Bone Disease: A Retrospective Cohort Study. JCO Oncol Pract 0, OP-25-00935 DOI:10.1200/OP-25-00935 October 1, 2026. 

Overview

Researchers reviewed 350 patients to compare bone complications and use of bone-strengthening medicines among African American and White patients with newly diagnosed myeloma. African American patients were less likely to receive these medicines and received fewer doses. Overall postdiagnosis bone-event rates did not differ significantly, but patients with early bone complications showed important gaps in subsequent preventive treatment. 

"Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study"

Source

Richter, J., Dhodapkar, M., Shah, M.R. et al. Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01636-2 October 1, 2026. 

Overview

This analysis assessed infection patterns and prevention measures in 117 patients receiving linvoseltamab in LINKER-MM1. Infections were common, including serious infections, but event rates declined after six months. Immunoglobulin replacement was associated with a possible reduction in serious infections, although the estimate was uncertain. The purpose was to guide infection monitoring and supportive care during treatment. 

"Bridging therapy response and type as determinants of cilta-cel outcomes in relapsed/refractory multiple myeloma"

Source

Hansen, D.K., Reid, B.M., Grajales-Cruz, A. et al. Bridging therapy response and type as determinants of cilta-cel outcomes in relapsed/refractory multiple myeloma. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01633-5 October 1, 2026. 

Overview

Researchers examined how treatment given while patients awaited cilta-cel CAR T-cell therapy related to later outcomes. In a retrospective cohort of 192 patients, lowering disease burden during bridging therapy was associated with longer progression-free survival and fewer severe neurologic events. Toxicity also varied by bridging regimen. These associations may inform treatment planning but do not prove which bridging approach is best. 

"Method Comparison of the Binding Site and Diazyme Serum Free Light Chain Assays on the Roche cobas c502"

Source

Spencer Seely, Megan Palacio, Michael Kelner, Robert Fitzgerald, Raymond Suhandynata, B-112 Method Comparison of the Binding Site and Diazyme Serum Free Light Chain Assays on the Roche cobas c502, Clinical Chemistry, Volume 72, Issue Supplement_1, October 2026, hvag086.426, https://doi.org/10.1093/clinchem/hvag086.426 

Overview

This laboratory comparison assessed whether Diazyme and Freelite free light chain tests produce comparable results on the same analyzer. Both showed good reproducibility, but systematic differences in kappa, lambda, and their ratio could affect disease monitoring. The findings highlight the need for assay-specific interpretation and a new baseline when patients switch testing methods. 

"The study of serum monoclonal protein (M-protein) glycosylation patterns for risk stratification in multiple myeloma"

Source

Priscilla Yeung, Chenyin Lu, Ethan Boneh, Danya Ortiz, Yajing Liu, Brian Xu, Justin Barthel, Farida Elgebaly, David Iberri, Ruben Luo, B-129 The study of serum monoclonal protein (M-protein) glycosylation patterns for risk stratification in multiple myeloma, Clinical Chemistry, Volume 72, Issue Supplement_1, October 2026, hvag086.437, https://doi.org/10.1093/clinchem/hvag086.437 

Overview

Researchers propose using high-resolution mass spectrometry to examine sugar structures attached to monoclonal proteins. Their goal is to determine whether these patterns could improve estimates of progression risk in precursor conditions or help guide myeloma treatment. The supplied abstract describes the rationale and objective, without reporting study results or validating a clinical biomarker. 

"Evaluation of Serum Free Light Chains: A Method Comparison Between the Diazyme Assay on the Beckman-Coulter AU5800 and the Binding Site Assay on the Optilite Platform"

Source

Annalara Fischer, Karen Cost, Cierra Sharp, Nicole Pozzi, Morgan McCoy, Mohamed Hegazi, Mustafa Kawaaz, Saeed Jortani, B-135 Evaluation of Serum Free Light Chains: A Method Comparison Between the Diazyme Assay on the Beckman-Coulter AU5800 and the Binding Site Assay on the Optilite Platform, Clinical Chemistry, Volume 72, Issue Supplement_1, October 2026, hvag086.442, https://doi.org/10.1093/clinchem/hvag086.442 

Overview

This study aimed to compare two free light chain testing systems: Diazyme on the Beckman-Coulter AU5800 and Freelite on the Optilite platform. The purpose was to understand whether differences could affect diagnosis and tracking of plasma cell disorders. The supplied abstract contains background and the study objective, but no methods, results, or conclusions establishing agreement between the tests. 

"Diazyme and Freelite Serum Free Light Chain Assays Are Not Clinically Interchangeable at IMWG-Defined Decision Points"

Source

Stuart Morgan, Sanchia Sarin, Charlotte Crawford, Jake Fisher, Hannah Jones, Luke Moore, Syreeta Allen, Jamieleigh Logan, Sandro Trova, Claudia Fogl, B-137 Diazyme and Freelite Serum Free Light Chain Assays Are Not Clinically Interchangeable at IMWG-Defined Decision Points, Clinical Chemistry, Volume 72, Issue Supplement_1, October 2026, hvag086.444, https://doi.org/10.1093/clinchem/hvag086.444 

Overview

Researchers compared Diazyme and Freelite free light chain assays in 125 serum samples, focusing on thresholds used to diagnose myeloma and assess smoldering myeloma risk. Substantial measurement differences led to different classifications at those thresholds. The findings indicate that the two assays should not be treated as interchangeable when applying criteria developed with Freelite. 

"Lambda light chain multiple myeloma is less prevalent but more strongly associated with renal dysfunction than kappa subtypes"

Source

Bibek Poudel, Ibrahim Hashim, B-107 Lambda light chain multiple myeloma is less prevalent but more strongly associated with renal dysfunction than kappa subtypes, Clinical Chemistry, Volume 72, Issue Supplement_1, October 2026, hvag086.422, https://doi.org/10.1093/clinchem/hvag086.422 

Overview

This study aimed to describe the distribution of myeloma subtypes at a county hospital and compare kidney-related laboratory outcomes in lambda and kappa disease. Its purpose was to clarify whether light chain subtype is associated with renal dysfunction. The supplied abstract presents background and objectives only, so the comparative findings suggested by the title cannot be assessed from the excerpt. 

"PCIF1-mediated m6Am modification activates USP5/BRD4 axis to promote glycolysis-driven immunosuppression in multiple myeloma"

Source

Shifeng Long, Ting Ding, Lu Zhou, Weifang Gao, Qinglan Wang, Yan Liu, PCIF1-mediated m6Am modification activates USP5/BRD4 axis to promote glycolysis-driven immunosuppression in multiple myeloma, International Immunopharmacology, Volume 186, 2026, 117062, ISSN 1567-5769, https://doi.org/10.1016/j.intimp.2026.117062. October 1, 2026. 

Overview

This laboratory study investigated how the RNA-modifying protein PCIF1 helps myeloma cells use glucose and suppress immune attack. Reducing PCIF1 activity disrupted the USP5/BRD4 pathway, limited cancer-cell growth, and improved the function of cancer-killing T cells in experimental systems. The findings identify a potential treatment target, with clinical benefit yet to be established. 

"Diagnostic challenges posed by the wide morphological and immunophenotypic spectrum of plasma cell neoplasms"

Source

Chuang, SS., Chang, CC. Diagnostic challenges posed by the wide morphological and immunophenotypic spectrum of plasma cell neoplasms. Blood Res. 61, 61 (2026). https://doi.org/10.1007/s44313-026-00179-6 October 2, 2026. 

Overview

This review describes unusual plasma cell appearances and protein-marker patterns that can make myeloma and related disorders resemble other blood cancers. Through diagnostic examples, the authors explain why cell appearance must be interpreted alongside marker testing and other clinical information. The purpose is to help pathologists recognize uncommon variants and reduce diagnostic errors. 

"Patient preferences for treatment-free intervals in multiple myeloma: mixed-methods insights on monitoring trade-offs and supportive care improvements"

Source

Fleischer, A., Barakat, M., Peter, J. et al. Patient preferences for treatment-free intervals in multiple myeloma: mixed-methods insights on monitoring trade-offs and supportive care improvements. Support Care Cancer 34, 1050 (2026). https://doi.org/10.1007/s00520-026-11255-z October 2, 2026. 

Overview

Researchers surveyed 100 patients about time between active treatment contacts, monitoring, and opportunities to improve care. Many valued longer intervals for recovery and daily life, while most found checkups reassuring; only a small minority explicitly accepted more relapse risk for longer breaks. The findings describe patient preferences and do not establish that changing treatment schedules is safe. 

"Metabolic vulnerabilities in multiple myeloma: targeting iron and amino acid metabolism to induce ferroptosis"

Source

Li, Q., Zhang, W., Gao, G. et al. Metabolic vulnerabilities in multiple myeloma: targeting iron and amino acid metabolism to induce ferroptosis. Apoptosis 31, 238 (2026). https://doi.org/10.1007/s10495-026-02449-1 October 3, 2026. 

Overview

Researchers investigated whether iron and amino acid metabolism influence myeloma cells' vulnerability to ferroptosis, an iron-dependent form of cell death. Low transferrin levels in patient samples were associated with poorer outcomes. Combining transferrin with erastin increased cancer-cell death in laboratory and mouse experiments, providing a research direction rather than a treatment proven effective in patients. 

"Bone Marrow Adipocytes in Multiple Myeloma: Emerging Immunometabolic Interactions and Implications for Immunotherapy"

Source

Roque, A., Paiva, A., Seiça, R., & Geraldes, C. (2026). Bone Marrow Adipocytes in Multiple Myeloma: Emerging Immunometabolic Interactions and Implications for Immunotherapy. Cancers, 18(19), 3213. https://doi.org/10.3390/cancers18193213 October 4, 2026. 

Overview

This review examines how bone marrow fat cells may influence myeloma growth and immune-cell activity. It considers whether their metabolic and inflammatory effects could alter responses to antibodies, bispecific antibodies, and CAR T-cell therapy. Most evidence is preclinical or observational, so a direct role in resistance to current immunotherapies remains unproven. 

"Enriched Adaptive Immunity and Reduced Inflammatory Response in Plasma Cell Disorders of Self-Identified Black Patients"

Source

Hongwei Tang, William C Pilcher, Huihuang Yan, Annamalai Sivasankar, Jinzhuang Dou, Suganti Shivaram, Mariam Khanfar, Neeraj Sharma, Stacey J. Lehman, Shulan Tian, Surendra Dasari, Cinthya J Zepeda-Mendoza, Mahek Bai, Joselle Cook, Nadine Abdallah, Abiola Bolarinwa, Emilie I Anderson, Taxiarchis V . Kourelis, S Vincent Rajkumar, Shaji K. Kumar, Megan Weivoda, Felicia Gomez, Manoj Bhasin, Linda B Baughn; Enriched Adaptive Immunity and Reduced Inflammatory Response in Plasma Cell Disorders of Self-Identified Black Patients. Blood 2026; blood.2026033998. doi: https://doi.org/10.1182/blood.2026033998 October 5, 2026. 

Overview

Researchers analyzed bone marrow immune profiles in 320 people with plasma cell disorders to explore differences associated with African genetic similarity. Greater African genetic similarity was linked to distinct T-cell, natural killer-cell, and monocyte patterns, including stronger features of adaptive immune activity. The findings characterize biological variation and do not establish differences in treatment response or survival. 

"High-dose melphalan and autologous stem cell transplantation in multiple myeloma: efficacy and minimal residual disease’s impact on progression-free survival"

Source

Chen, M., Chen, G., Xu, J. et al. High-dose melphalan and autologous stem cell transplantation in multiple myeloma: efficacy and minimal residual disease’s impact on progression-free survival. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-17060-5 October 5, 2026. 

Overview

Researchers reviewed 50 newly diagnosed patients to assess response after high-dose melphalan and autologous stem cell transplantation, including the value of minimal residual disease testing. Complete response and MRD-negative rates increased after transplant. Sustained MRD negativity for at least one year was associated with favorable outcomes in a small exploratory analysis, requiring confirmation in larger studies. 

"Emergency diagnosis of multiple myeloma: a SEER-Medicare study"

Source

Oyinbo, A.G., Al Amin, S., LeBlanc, M.R. et al. Emergency diagnosis of multiple myeloma: a SEER-Medicare study. Cancer Causes Control 37, 175 (2026). https://doi.org/10.1007/s10552-026-02263-9 October 5, 2026. 

Overview

Using SEER-Medicare data, researchers examined how often older adults received a myeloma diagnosis after emergency department care and which factors were associated with that route to diagnosis. Among 20,437 patients, 37% had emergency involvement. Associations with social disadvantage, frailty, and other factors, alongside prior symptom-related visits, suggest opportunities to investigate earlier recognition of myeloma. 

"Long-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in transplant-ineligible multiple myeloma: final report of a phase II trial"

Source

Joshua N. Gustine, Elizabeth K. O'Donnell, Jacob P . Laubach, Andrew J. Yee, Carol Ann Huff, Irene M. Ghobrial, Jill N. Burke, Cynthia C. Harrington, Nikhil C. Munshi, Kenneth C. Anderson, Paul G. Richardson, Noopur S. Raje; Long-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in transplant-ineligible multiple myeloma: final report of a phase II trial. Clin Cancer Res 2026; https://doi.org/10.1158/1078-0432.CCR-26-0794 October 5, 2026. 

Overview

This final phase 2 report evaluated long-term outcomes with RVD-lite, a reduced-intensity combination of lenalidomide, bortezomib, and dexamethasone, in 50 patients ineligible for transplant. After a median six-year follow-up, median progression-free survival was 42 months and median overall survival was 76 months. Few patients stopped because of toxicity, supporting further study of regimens adapted to patient fitness. 

"Navigating the Immune Landscape: Balancing Efficacy and Toxicity of BCMA-Targeting Agents in Multiple Myeloma"

Source

Tang L, Feng W, Bai Y . Navigating the Immune Landscape: Balancing Efficacy and Toxicity of BCMA-Targeting Agents in Multiple Myeloma. Acta Haematol. 2026 Oct 5:1. doi: 10.1159/aha/abkag002. Epub ahead of print. 

Overview

This review examines how to balance the benefits of BCMA-targeted immunotherapies with their immune-related toxicities and mechanisms of resistance. It covers CAR T cells and bispecific antibodies, including inflammatory syndromes, neurologic effects, and loss of the treatment target. The authors discuss risk-based management, treatment sequencing, and combinations intended to improve long-term disease control. 

"Gastric involvement in multiple myeloma-associated AL amyloidosis: a case with serial endoscopy and a pooled analysis of 30 published cases"

Source

Wang L, You J, Cheng G and Shen X (2026) Gastric involvement in multiple myeloma-associated AL amyloidosis: a case with serial endoscopy and a pooled analysis of 30 published cases. Front. Oncol. 16:1960604. doi: 10.3389/fonc.2026.1960604 

Overview

This report combines one patient's course with 30 published cases to clarify how myeloma-associated AL amyloidosis can affect the stomach. Symptoms and endoscopic appearances were varied and could resemble other conditions. The authors emphasize considering amyloid deposition when persistent gastrointestinal symptoms remain unexplained and using adequate biopsies, specialized staining, and protein typing to establish the diagnosis. 

"Gustatory dysfunction under talquetamab therapy in multiple myeloma: a cross-sectional study of patient-reported course, nutritional changes, and quality of life"

Source

Fleischer, A., Burger, C., Roll, M. et al. Gustatory dysfunction under talquetamab therapy in multiple myeloma: a cross-sectional study of patient-reported course, nutritional changes, and quality of life. Support Care Cancer 34, 1059 (2026). https://doi.org/10.1007/s00520-026-11288-4 October 5, 2026. 

Overview

Researchers assessed taste changes, nutrition, and quality of life in 32 patients receiving talquetamab. All reported taste disturbances, and poorer taste-test performance was associated with reduced appetite and lower reported health status; half reported weight loss. The study highlights supportive-care needs, but its single-time-point design cannot determine causation, recovery over time, or effects on adherence. 

"Evaluation of a multiple myeloma synthetic cell mimic as an assay control for flow cytometry"

Source

Lee, D. H., Liu, M., Palla, K., Biswas, S., Gunturu, S. P ., Kerfs, B., Valenteros, K., Kotanchiyev, S., Kaiser, S., & Dell'Aringa, J. (2026). Evaluation of a multiple myeloma synthetic cell mimic as an assay control for flow cytometry. Cytometry Part B: Clinical Cytometry, 1-10. https://doi.org/10.1002/cyto.b.70075 October 5, 2026. 

Overview

Researchers developed synthetic cells to improve quality control in flow cytometry tests used in myeloma trials. The mimics reproduced relevant plasma-cell and B-cell markers more fully than a commonly used cell line and showed consistent performance and storage stability. The purpose is to improve confidence in laboratory measurements, rather than to test a treatment or diagnostic outcome in patients. 

"Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05)"

Source

Corre, J., Lambert, J., Bobin, A., Manier, S., Perrot, A., Karlin, L., Roussel, M., Bigot, N., Benbrahim, O., Allangba, O., Rey, P ., Dorvaux, V ., Vignon, M., Roland, V ., Garidi, R., Bastie, J.-N., Chretien, M.-L., Godet, S., Montes, L., Cherel, B., Vekhoff, A., Chalopin, T., Slama, B., Laribi, K., Dingremont, C., Roul, C., Richez-Olivier, V ., Mariette, C., Rigaudeau, S., Calmettes, C., Dib, M., Tiab, M., Vincent, L., Delaunay, J., Maheo, S., Schavgoulidze, A., Frenzel, L., Godmer, P ., Calloch, R.L., Chalayer, E., Gardeney, H., Macro, M., Royer, B., Harel, S., Decaux, O., Arnulf, B., Belhadj, K., Gontier, A., Touzeau, C., Mohty, M., Moreau, P ., Facon, T., Hulin, C. and Leleu, X. (2026), Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05). HemaSphere, 10: e70482. https://doi.org/10.1002/hem3.70482 October 5, 2026. 

Overview

This BENEFIT analysis examined whether adding bortezomib to isatuximab, lenalidomide, and dexamethasone improved MRD responses in transplant-ineligible patients, including those meeting a newer high-risk definition. The four-drug regimen produced higher MRD-negative rates overall and in high-risk disease. Sustained-response results favored the combination, but some subgroup differences were inconclusive and survival follow-up remained immature. 

"Intra-and inter-observer agreement of IMPeTUs in multiple myeloma: a blinded repeated-reader study with independent multi-institutional readers"

Source

Bilgic, S., Akovali, B., Toplutas, K.N. et al. Intra-and inter-observer agreement of IMPeTUs in multiple myeloma: a blinded repeated-reader study with independent multi-institutional readers. Sci Rep (2026). https://doi.org/10.1038/s41598-026-74515-2 October 5, 2026. 

Overview

Researchers asked how consistently clinicians apply the IMPeTUs framework when reading myeloma PET/CT scans. Three specialists from different institutions assessed 50 scans twice. Agreement was stronger for some bone-lesion measures and weaker for fractures and disease outside the marrow. The findings support clearer definitions and targeted training to improve the reproducibility of imaging assessments. 

"Single-cell and bulk transcriptomic profiling of M2-like tumor-associated macrophages reveals a prognostic signature and an inflammation-metabolism crosstalk program in multiple myeloma"

Source

Hui Zhao, Jing Kang, Huiling Ouyang, Xiaye Lv, Ziying Huang, Bingni Zhao, Kai Wang, Single-cell and bulk transcriptomic profiling of M2-like tumor-associated macrophages reveals a prognostic signature and an inflammation-metabolism crosstalk program in multiple myeloma, Translational Oncology, Volume 72, 2026, 102983, ISSN 1936-5233, https://doi.org/10.1016/j.tranon.2026.102983. October 2026. 

Overview

Researchers combined single-cell gene-expression data with larger patient datasets to identify myeloma-associated macrophage populations and develop a survival-prediction signature. The resulting model separated groups with different outcomes and immune characteristics in research datasets. It may help identify future biomarkers and treatment targets, but its usefulness for routine patient management requires prospective clinical validation. 

"Chromatin-informed cell-free DNA approach for detection of clinically measurable disease in multiple myeloma"

Source

Palak Bajaj, Dor David Abelman, Ping Luo, Michele Ceccarelli, Jonathan H Schatz, Dionysios C. Watson, Christian N Baker, Ava Amidei, Edus H Warren, Benjamin T. Diamond, Alexander M. Lesokhin, Neha S. Korde, Urvi A. Shah, Sham Mailankody, Hani Hassoun, Eric L Smith, Dickran Kazandjian, Sacha Gnjatic, Trevor J. Pugh, Damian J Green, Ola Landgren, David G Coffey; Chromatin-informed cell-free DNA approach for detection of clinically measurable disease in multiple myeloma. Blood Adv 2026; bloodadvances.2026022335. doi: https://doi.org/10.1182/bloodadvances.2026022335 October 6, 2026. 

Overview

Researchers developed MATADOR, a blood-based method that uses cell-free DNA fragmentation patterns to detect clinically measurable myeloma without first profiling an individual's tumor. The method distinguished measurable from unmeasurable disease well in a separate test dataset. The study supports further development of less invasive assessment but does not establish equivalence to sensitive bone marrow MRD testing. 

"MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study"

Source

Madan S, Costello C, Lipe B et al. MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study The Lancet Haematology, 2026; 0 October 6, 2026. 

Overview

This first-in-human phase 1 trial evaluated the safety, drug behavior, and early activity of MK-4002, a BCMA-targeting trispecific T-cell engager, in 97 heavily pretreated patients. Responses supported further testing of a 12-mg dose. Serious and severe adverse events were common, and one treatment-related death occurred. Larger studies are needed to clarify benefit and safety. 

"MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma"

Source

Facon, T., Cook, G., Usmani, S.Z. et al. MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma. Leukemia (2026). https://doi.org/10.1038/s41375-026-03128-5 October 6, 2026. 

Overview

This long-term MAIA analysis examined whether the benefits of adding daratumumab to lenalidomide and dexamethasone differed by frailty. Progression-free survival and deep responses improved across frailty groups. Overall survival benefit was established in non-frail patients, while the estimate in frail patients remained statistically uncertain. Frailty was assessed retrospectively, which limits the subgroup conclusions. 

"SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models"

Source

Bird, S.A., Licciardello, M.P ., Morales, S. et al. SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models. Blood Cancer J. 16, 172 (2026). https://doi.org/10.1038/s41408-026-01632-6 September 6, 2026. 

Overview

Researchers investigated whether blocking SETD2, an enzyme involved in gene regulation, could target myeloma resistant to immunomodulatory drugs or CELMoDs. Resistant cell lines were more sensitive to SETD2 inhibition, particularly in a model carrying t(4;14). These preclinical findings support further drug development, but the proposed strategy has not been validated in patients with resistant disease. 

"Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma"

Source

Xu, J., Liu, L., Xie, W. et al. Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma. Nat Med (2026). https://doi.org/10.1038/s41591-026-04704-z October 6, 2026. 

Overview

This follow-up assessed the durability and safety of an experimental therapy that generates BCMA CAR T cells inside the body, initially tested in four patients without cell collection or lymphodepletion. One patient maintained a stringent complete response for 15 months, while three progressed and died during follow-up. The very small study highlights both feasibility and the need to improve response persistence. 

"T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis"

Source

Merz, M., Souto Filho, J.T., Voorhees, P .M. et al. T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis. J Hematol Oncol 19, 83 (2026). https://doi.org/10.1186/s13045-026-01850-2 October 7, 2026. 

Overview

Researchers indirectly compared CAR T-cell and bispecific-antibody regimens used after early myeloma relapse by analyzing four randomized trials. Treatment rankings changed when differences between trials were considered, preventing reliable conclusions that one regimen was more effective than another. The analysis supports considering toxicity, patient needs, treatment sequence, access, and cost while awaiting direct comparative evidence. 

"BCMA-Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management"

Source

M. Martino, E. Bilardi, M. Pitea, et al., “ BCMA-Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management,” European Journal of Haematology (2026): 1-16, https://doi.org/10.1111/ejh.70328. October 7, 2026. 

Overview

This review compares BCMA-targeted antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies in early relapsed myeloma. It summarizes trial evidence on effectiveness, response durability, toxicities, and treatment sequencing. The purpose is to help clinicians interpret the strengths and practical demands of each approach, while recognizing that cross-trial results do not replace direct comparisons. 

"Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma"

Source

O'Neill, C., Broekmans, M.E.C., Korst, C.L.B.M., Krevvata, M., Dal Collo, G., Groen, R.W., Li, B., Baglio, S.R., Philippar, U., Pillarisetti, K., Zweegman, S., Vishwamitra, D., Mutis, T. and van de Donk, N.W.C.J. (2026), Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma. HemaSphere, 10: e70487. https://doi.org/10.1002/hem3.70487 October 7, 2026. 

Overview

This preclinical study tested whether ramantamig, which targets both BCMA and GPRC5D while engaging T cells, could address variation in myeloma-cell targets. It killed myeloma cells more effectively than single-target comparators in cell lines and patient bone marrow samples. The findings support dual-target development but do not establish clinical response durability or prevention of resistance in patients. 

"Approval-Standardized Postmarketing Safety Reporting Phenotypes of Talquetamab Versus BCMA-Directed Bispecific Antibodies in Multiple Myeloma"

Source

He Zhu, Wenxi He, Approval-Standardized Postmarketing Safety Reporting Phenotypes of Talquetamab Versus BCMA-Directed Bispecific Antibodies in Multiple Myeloma, Leukemia Research, 2026, 108338, ISSN 0145-2126, https://doi.org/10.1016/j.leukres.2026.108338. October 7, 2026. 

Overview

Researchers compared adverse-event reporting patterns for talquetamab and BCMA-directed bispecific antibodies using equal postapproval observation windows. Talquetamab reports more often included taste, nail, skin, and weight-related problems, while BCMA-directed reports more often included infection. These findings may guide surveillance, but reporting databases cannot establish event incidence, comparative treatment risk, or causation. 

"A natural product-derived degrader (COT-01): cortisone-based CRBN recruitment for cyclin D2 degradation in multiple myeloma"

Source

Seung Hyeong Lee, Su Ah. Kim, Kyeong Eun Lee, Yewon Lim, Hyo Jung Ahn, Doyoun Kim, Woo Dae Jang, Hwan Jung Lim, Jeong Hyun Lee, Kwang-Seok Oh, A natural product-derived degrader (COT-01): cortisone-based CRBN recruitment for cyclin D2 degradation in multiple myeloma, Bioorganic Chemistry, 2026, 110615, ISSN 0045-2068, https://doi.org/10.1016/j.bioorg.2026.110615. October 7, 2026. 

Overview

Researchers tested COT-01, a cortisone-derived compound designed to recruit cereblon and promote breakdown of cyclin D2, a protein involved in cell division. It reduced cyclin D2, inhibited myeloma-cell growth, and suppressed tumors in mice. The work identifies an experimental protein-degradation strategy that still requires further safety testing and clinical evaluation. 

"Dysregulation of the Bone Marrow Immune Microenvironment and Clinical Outcomes in Multiple Myeloma"

Source

Ghirardi, M. P ., Brandalise, P ., Berraondo, M., Seehaus, C., Leão, D., Pericole, F . V ., Magalhães, R. J. P ., Filho, Crusoé, E., Maiolino, A., Hungria, V ., Saini, K. S., & Da Cunha Junior, A. D. (2026). Dysregulation of the Bone Marrow Immune Microenvironment and Clinical Outcomes in Multiple Myeloma. Immuno, 6(4), 66. https://doi.org/10.3390/immuno6040066 October 7, 2026. 

Overview

This review examines how changes in bone marrow immune cells and their interactions with myeloma cells relate to progression, resistance, and outcomes. It brings together evidence from advanced profiling methods to explore potential immune-based biomarkers and treatment strategies. The purpose is to inform more individualized care through future validation of markers beyond conventional tumor genetics and staging. 

"Symptom Burden and Quality of Life in Multiple Myeloma: A Multicenter Study"

Source

Jebrin Alkrinawi, Nizar Abu Hamdeh, Mohammad Alnees, Ibraheem AbuAlrub, Abdalaziz Darwish, Duha Najajra, Osama Ewidat, Yahya Z. Fraitekh, Mohammad Masu'd, Omar Hammam Salloum, Reem J Saad, Nasim Abukaresh, Mustafa A. Shahrori, Mahdi Awwad, Basem Bali, Nora I. Baraghithi, Ahmad Alhashlamon, Yasmin Ahmad Rjoub, Mohammad Maswadeh, Zeina Sinnokrot, Firas Besharieh, Majde Abu Khaled, Rashed Saed, Rafufan Alsaied, Waed Awad, Nuha Riyad, Sarah Awad, Bashar Dawood, Yousef Abdelhay Yousef Abu Rayyan, Loay Shaheen, Majdi Khaled Zaid, Mohammed Manassra, Khairi Alzirei, Ali Abdullah, Haitham Abu Khadija; Symptom Burden and Quality of Life in Multiple Myeloma: A Multicenter Study. Oncology 2026; https://doi.org/10.1159/ocl/aebag019 October 7, 2026. 

Overview

Researchers studied 250 previously treated patients at six hospitals in the West Bank to examine how symptoms relate to quality of life. Greater symptom severity and interference were associated with poorer physical function, more pain, and worse overall quality-of-life scores. The findings support routine symptom assessment to identify supportive-care needs, without proving that a particular intervention improves outcomes. 

"Translocation-induced enhancer rewiring reveals cryptic oncogenic circuits in multiple myeloma"

Source

Enrun Zheng et al.,Translocation-induced enhancer rewiring reveals cryptic oncogenic circuits in multiple myeloma.Sci. Adv.12,eaeg9610(2026).DOI:10.1126/sciadv.aeg9610 October 7, 2026. 

Overview

Researchers developed TransFinder to detect hidden chromosome rearrangements and identify how they activate cancer-driving genes. Applying the approach to myeloma uncovered previously unrecognized gene-regulation changes, and laboratory experiments supported a role for CBX7 in cell growth. The work aims to improve understanding of disease biology and identify potential targets, with clinical application requiring further validation. 

"Dual antigen targeting with Talquetamab Plus Teclistamab: a new horizon for extramedullary multiple myeloma?"

Source

Javed, B., & Kumar, S. (2026). Dual antigen targeting with Talquetamab Plus Teclistamab: a new horizon for extramedullary multiple myeloma? Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2026.2746598 October 7, 2026. 

Overview

This expert commentary evaluates the rationale and emerging evidence for combining talquetamab and teclistamab in myeloma that has spread outside bone marrow. Targeting both GPRC5D and BCMA may address loss or uneven expression of either target. Early trials show substantial activity, but serious infections, treatment-related deaths, limited follow-up, and persistent immune resistance remain important concerns. 

"Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies"

Source

Gasoyan, H., Raza, S., Rothberg, M.B. et al. Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies. Blood Cancer J. 16, 173 (2026). https://doi.org/10.1038/s41408-026-01645-1 October 7, 2026. 

Overview

This research letter compares survival among Black and White patients diagnosed in a large integrated health system during the triplet and quadruplet treatment era. Among 1,209 patients, five-year survival was comparable in weighted analyses, and Black patients had lower adjusted mortality. The findings support efforts to improve equitable access, while lower transplant use among Black patients remained an unresolved disparity. 

"Single-cell analysis of the tumor microenvironment landscape across the disease spectrum of multiple myeloma"

Source

Minghao Dang, Luz Yurany Moreno Rueda, Maria Jose Acevedo Calado, Hima Bansal, David A. Berrios Nolasco, Amishi U. Vora, Jonathan D. Mejia, Mei Huang, Wei Tan, Li Qin, Yunhe Liu, Yang Liu, David E. Mery, Yan Cheng, Fenghuang Zhan, John D. Shaughnessy, Qing Yi, Pei Lin, Mahmoud R. Gaballa, Oren Pasvolsky, Hans C. Lee, Sheeba K. Thomas, Donna M. Weber, Krina K. Patel, Melody R. Becnel, Jing Christine Ye, Isere Kuiatse, Elisabet E. Manasanch, Linghua Wang, Robert Z. Orlowski; Single-cell analysis of the tumor microenvironment landscape across the disease spectrum of multiple myeloma. Blood 2026; 148 (15): 1893-1910. doi: https://doi.org/10.1182/blood.2025032630 October 8, 2026. 

Overview

Researchers profiled individual bone marrow immune cells from 235 patients across myeloma precursor states and active disease to map changes in the tumor environment. They identified five recurring immune-community patterns associated with disease features, treatment response, and outcomes. The work provides a research atlas that may inform future biomarkers and immunotherapies tailored to specific immune environments. 

"The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma"

Source

Phuong Thao Pham, Hoang Viet Nguyen, Minh Phuong Vu, The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma, Leukemia Research Reports, 2026, 100615, ISSN 2213-0489, https://doi.org/10.1016/j.lrr.2026.100615. October 8, 2026. 

Overview

Researchers examined KRAS, NRAS, BRAF, and TP53 mutations in 117 newly diagnosed patients to assess their prognostic value alongside chromosome abnormalities. Some RAS/RAF-mutated groups had better survival than the TP53-mutated group, but differences were not apparent within high-risk chromosome groups. The findings emphasize interpreting mutations in their broader genetic context rather than as stand-alone risk markers. 

"Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma"

Source

Potthoff, K., Uhlig, J., Heyde, E.v.d. et al. Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma. Ann Hematol (2026). https://doi.org/10.1007/s00277-026-07302-8 October 8, 2026. 

Overview

The prospective CARO study assessed adherence, effectiveness, safety, and quality of life with three carfilzomib-based combinations in routine German practice. Among 359 patients, adherence exceeded 90%, quality of life remained stable, and pain improved after six months. Outcomes supported activity in everyday care, but the nonrandomized design does not establish superiority among the regimens. 

"Monoclonal Gammopathy in Autoimmune Diseases: Marker, Consequence, Pathogenetic Factor-Or Coincidence?"

Source

Műzes, G., & Sipos, F . (2026). Monoclonal Gammopathy in Autoimmune Diseases: Marker, Consequence, Pathogenetic Factor-Or Coincidence? Biomedicines, 14(10), 2288. https://doi.org/10.3390/biomedicines14102288 October 8, 2026. 

Overview

This review examines whether monoclonal gammopathy in autoimmune disease is a marker of immune activation, a consequence of inflammation, a contributor to illness, or a coincidental finding. It compares proposed biological mechanisms with epidemiologic evidence, including screening data showing no significant adjusted association with MGUS. The purpose is to clarify competing explanations and priorities for future research. 

"Investigating Denosumab Interference in Serum Protein Electrophoresis"

Source

Sungyu Jee, Jungjun Lee, Hanwool Cho, Hyojin Chae, Investigating Denosumab Interference in Serum Protein Electrophoresis, The Journal of Applied Laboratory Medicine, 2026;, jfag135, https://doi.org/10.1093/jalm/jfag135 October 8, 2026. 

Overview

Researchers investigated whether denosumab could be mistaken for a patient's monoclonal protein in laboratory monitoring tests. Although the drug produced a recognizable pattern in laboratory experiments, no clinically relevant interference was detected in 110 treated patients. Mass spectrometry helped distinguish a suspicious peak from the drug, reducing concern about this source of testing error in the studied setting. 

"Targeting FcRL5 in multiple myeloma: biological rationale and strategic sequencing beyond BCMA and GPRC5D"

Source

Fu, X., Chen, M., Hu, X. et al. Targeting FcRL5 in multiple myeloma: biological rationale and strategic sequencing beyond BCMA and GPRC5D. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01639-z October 9, 2026. 

Overview

This review assesses FcRL5 as an alternative immunotherapy target after BCMA- or GPRC5D-directed treatment. It examines the biological rationale, early clinical activity of cevostamab, other experimental approaches, resistance, and treatment sequencing. The purpose is to guide future development and study of FcRL5 strategies, with response durability and optimal sequencing still needing clarification. 

"Associations of Baseline Cognitive and Psychosocial Function with Clinical Outcomes After Autologous Stem Cell Transplantation in a Multiple Myeloma Sample"

Source

Rueda-Lara, M., Komanduri, K. V ., Pereira, D., Lekakis, L., Wang, T. P ., Jimenez, A. M., Beitinjaneh, A., Holtzman, N. G., Green, D. J., Goodman, M., Benjamin, C. L., Harvey, P . D., & Wright, B. J. (2026). Associations of Baseline Cognitive and Psychosocial Function with Clinical Outcomes After Autologous Stem Cell Transplantation in a Multiple Myeloma Sample. Cancers, 18(20), 3264. https://doi.org/10.3390/cancers18203264 October 9, 2026. 

Overview

Researchers assessed whether cognitive function, anxiety, and other psychosocial measures before transplant were associated with recovery and survival in 245 patients. Higher baseline anxiety was linked to longer hospitalization after engraftment. Prolonged hospitalization and, in a secondary analysis, poorer delayed memory were associated with mortality. These observational findings may help identify patients needing additional assessment and support. 

"Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation"

Source

Fortoeș, D., Antohe, I., Cianga, V .-A., Minciună, C.-D., Nicorici, E., Dolachi-Pelin, E., Zlei, M., Mentel, M., Dragoș, L., Ivanov, I., Uhl, A., Tomuleasa, C., & Dăscălescu, A. (2026). Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Medical Sciences, 14(6), 659. https://doi.org/10.3390/medsci14060659 October 9, 2026. 

Overview

Researchers examined whether the timing of EASIX, a blood-test index reflecting vascular stress, affects its ability to identify higher-risk transplant patients. In a retrospective cohort of 99 patients, higher scores at diagnosis were associated with poorer survival outcomes, while scores immediately before transplant showed no consistent association. Larger independent studies are needed to validate the timing and clinical usefulness. 

"Healthcare resource utilisation and costs of chemotherapy and autologous haemopoietic cell transplantation of patients with multiple myeloma in China: a multi-centre retrospective analysis"

Source

Wang Y , Li L, Ji P , Yu C, Wu Q, Wu W, Pan D. Healthcare resource utilisation and costs of chemotherapy and autologous haemopoietic cell transplantation of patients with multiple myeloma in China: a multi-centre retrospective analysis. BMJ Open. 2026 Oct 12;16(10):e122906. doi: 10.1136/bmjopen-2026-122906. 

Overview

Researchers reviewed healthcare use and direct medical costs for 1,238 patients at three hospitals in China. Costs rose with later treatment lines and resistance to bortezomib or lenalidomide, while adjusted costs declined over calendar time alongside pricing reforms. The study aims to inform resource planning and economic evaluations, without proving that the reforms caused the observed reduction. 

"Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE)"

Source

W. Nina, S. Martin, T. Andreas, et al., “Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE),” Journal of Clinical Apheresis 41, no. 5 (2026): e70188, https://doi.org/10.1002/jca.70188. October 12, 2026. 

Overview

The randomized OPTIMIZE trial tested whether adding plerixafor improved stem cell collection in patients with intermediate mobilization capacity. All plerixafor recipients collected the target amount in one session, compared with none receiving placebo, although subsequent engraftment and immune recovery were similar. Enrollment stopped early at 21 patients, limiting conclusions about longer-term benefits and broader application. 

"Factors Associated With Symptom Profiles Among Chinese Patients With Multiple Myeloma: A Latent Profile Analysis"

Source

T. Wang, Y . Lin, L. Tang, et al., “Factors Associated With Symptom Profiles Among Chinese Patients With Multiple Myeloma: A Latent Profile Analysis,” Cancer Medicine 15, no. 10 (2026): e72312, https://doi.org/10.1002/cam4.72312. October 12, 2026. 

Overview

Researchers surveyed 265 patients in China to identify distinct symptom patterns and factors associated with greater burden. Three groups emerged, ranging from relatively low burden to widespread severe symptoms. Older age and poorer physical performance were associated with higher-burden profiles. The findings may inform targeted symptom assessment, but follow-up studies are needed to test profile-based supportive care. 

"Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy"

Source

Shincovich, C.I., Chewcharat, A., Adomi, M., McGee, E.E., Kim, R., Pirovano, M., Prosek, J., Devarakonda, S.S., Leisring, J., Obole, E., Tharakan, J., Vaishnav, A., Klomjit, N., Likasitwatanakul, P ., Andrzejewski, C., Hassan, S., Abraham, A.E., O'Hearn, L., Garcia Valencia, O., McDonald, J.S., Sheikh, M.S., Kim, B.M., Koirala, P ., Malik, A.B., Bansal, A., McMahon, B.A., Teruel, B., Kala, J., Geara, A., Tillquist, K., Kanduri, S., Szalat, R., Aijaz, A., Mamlouk, O., Ziolkowski, S.L., Caldwell, J., Bonilla, M., Ismail, N., Amarapurkar, P .D., Franz, J.K., Balogun, R.A., Goggins, E., Bassil, C., Thapa, S., Baz, R., Shin, D.S., Zuckerman, J.E., Kahlon, K., Shah, Y ., Jhaveri, K.D., Thakur, R., Zhang, J., Deshpande, P ., Abramson, M.H., Syed, D., Rajasekaran, A., Pujari, A., Raval, J.S., Bosques, L., Porterfield, F .H., Somasundaram, E. V ., Wells, S.L., Rubman, M.B., Pérez, R.S., Peterkin, A.C., Lima, C.S.N.H., Murakami, N., Terashita, M., Kim, E.B., Mosaheb, K., Hanna, P .E., Nadeem, O., Leaf, D.E., Chowdhury, R.B., Stowell, S.R., Yee, A.J., Leung, N. and Gupta, S. (2026), Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy. Am J Hematol. https://doi.org/10.1002/ajh.70516 October 12, 2026. 

Overview

Using records from 25 U.S. cancer centers, researchers assessed whether early plasma exchange or daratumumab was associated with kidney recovery in light chain cast nephropathy. Neither approach showed a statistically conclusive overall association with recovery at 90 days. Plasma-exchange subgroup findings were exploratory. The observational design leaves uncertainty about treatment benefit and supports further rigorous investigation. 

"Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study"

Source

Boot IWA, Weltin AL, de Graaf Y , Vrijhoef HJM. Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. JMIR Cancer. 2026 Oct 13;12:e92253. doi: 10.2196/92253. 

Overview

This early economic assessment modeled whether AI-supported hospital production of CAR T cells could offer value compared with commercial cilta-cel and standard care in Germany. The model projected lower costs and better health outcomes for the developmental platform. Because its clinical inputs relied on estimates and assumptions, the findings are projections requiring confirmation rather than evidence of demonstrated patient benefit. 

"Population Pharmacokinetic Estimation of Melphalan Exposure Predicts Disease Control and Toxicity after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma"

Source

Natalia Tijaro Ovalle, Andrew Lin, Nancy Cruz Sitner, Ryan Schofield, Brenden Bready, Mithat Gonen, A. Zara Herskovits, Ross S. Firestone, Hamza Hashmi, Hani Hassoun, Malin Hultcrantz, Neha S. Korde, Alexander M. Lesokhin, Kylee Maclachlan, Sham Mailankody, Francesco Maura, Maximillian Merz, Sridevi Rajeeve, Urvi A. Shah, Caryln Rose Tan, Saad Z. Usmani, Miguel-Angel Perales, Parastoo B. Dahi, Eric M. Jurgens, David J. Chung, Michael Scordo, Heather J. Landau, Sergio A. Giralt, Gunjan L. Shah, Population Pharmacokinetic Estimation of Melphalan Exposure Predicts Disease Control and Toxicity after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma, Transplantation and Cellular Therapy, 2026, ISSN 2666-6367, https://doi.org/10.1016/j.jtct.2026.10.015. October 13, 2026. 

Overview

Researchers examined how measured and modeled melphalan exposure related to disease control and toxicity after autologous transplantation in 148 patients. Higher exposure was associated with some better response and progression outcomes, but also longer hospitalization and more toxicity; overall survival did not differ. The purpose is to support prospective testing of dosing that balances effectiveness with tolerability. 

"Head-to-Head Comparison Between [18F]FDG and [68Ga]Ga-Pentixafor PET/CT in Multiple Myeloma: A Systematic Review and Meta-Analysis"

Source

Albano, D., Tasevski, S., Rapa, M., Nanni, C., & Treglia, G. (2026). Head-to-Head Comparison Between [18F]FDG and [68Ga]Ga-Pentixafor PET/CT in Multiple Myeloma: A Systematic Review and Meta-Analysis. Cancers, 18(20), 3305. https://doi.org/10.3390/cancers18203305 October 13, 2026. 

Overview

This systematic review compared standard FDG PET/CT with CXCR4-targeted pentixafor PET/CT in 11 studies involving 347 patients. Pentixafor imaging had a higher patient-level detection rate in the pooled evidence. The findings support further evaluation as a complementary imaging method and potential aid to treatment selection, but stronger studies are needed before establishing its clinical role. 

"Clinical and Laboratory Factors Associated with Serious Infections in Multiple Myeloma: A Real-World Study"

Source

Odabaşı Giden, A., Şahin, O., & Ozatli, D. (2026). Clinical and Laboratory Factors Associated with Serious Infections in Multiple Myeloma: A Real-World Study. Current Oncology, 33(10), 615. https://doi.org/10.3390/curroncol33100615 October 13, 2026. 

Overview

Researchers reviewed 104 patients to identify accessible clinical and laboratory markers associated with infections requiring hospitalization. Dialysis at diagnosis and failure to respond to treatment were independently associated with serious infection, while the baseline neutrophil-to-lymphocyte ratio was not. The study aims to improve risk-based supportive care; observed immunoglobulin-treatment associations cannot establish that replacement therapy caused infections. 

"Ki-67 Proliferation Index Improves the Prognostic Stratification Accuracy of International Staging System in Newly Diagnosed Multiple Myeloma"

Source

Qin, X., Zhao, J., Bai, Q., Qiu, Q., Li, S., Zhang, Y ., Zhang, L., & Ma, Y . (2026). Ki-67 Proliferation Index Improves the Prognostic Stratification Accuracy of International Staging System in Newly Diagnosed Multiple Myeloma. Cancers, 18(20), 3312. https://doi.org/10.3390/cancers18203312 October 13, 2026. 

Overview

Researchers assessed whether Ki-67, a marker of cell proliferation, could add prognostic information to standard myeloma staging. In 307 newly diagnosed patients, a Ki-67 index above 10% was associated with shorter progression-free and overall survival. Combining Ki-67 with International Staging System categories separated risk groups, but the proposed approach needs validation beyond this retrospective cohort. 

"Elevated Risks for Depression and Anxiety Following Diagnosis of Multiple Myeloma"

Source

K. F . K. Rydahl, A. K. Øvlisen, T. A. Horsbøl, et al., “Elevated Risks for Depression and Anxiety Following Diagnosis of Multiple Myeloma,” European Journal of Haematology (2026): 1-10, https://doi.org/10.1111/ejh.70339. October 13, 2026. 

Overview

Using Danish registries, researchers compared depression and anxiety after myeloma diagnosis with outcomes in matched people from the general population. Risk was elevated in both active and smoldering myeloma, particularly during the first year. The findings highlight the need to recognize psychological distress early, while the observational design does not identify which preventive or supportive interventions work best. 

"Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China"

Source

Zuo G, Liu A, Zhu Z, Bao L, Liu L, Gao Y , Chen W, Fu R, Chen W. Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China. J Comp Eff Res. 2026 Oct 13:e260146. doi: 10.57264/cer-2026-0146. 

Overview

This economic model compared a treatment strategy transitioning to ixazomib, lenalidomide, and dexamethasone with daratumumab, lenalidomide, and dexamethasone for transplant-ineligible patients in China. The model projected lower lifetime costs and more quality-adjusted survival with the ixazomib strategy. Results depended on treatment-discontinuation and progression assumptions and need confirmation in comparative real-world studies. 

"The Fiscal Consequences Attributed to Multiple Myeloma in Slovakia: There is No Small Disease"

Source

Babela, R., Kotsopoulos, N. & Connolly, M.P . The Fiscal Consequences Attributed to Multiple Myeloma in Slovakia: There is No Small Disease. Bratisl. Med. J. (2026). https://doi.org/10.1007/s44411-026-00894-7 October 14, 2026. 

Overview

Researchers modeled myeloma's impact on Slovak public finances through healthcare spending, lost tax revenue, and additional social payments. The estimated 2023 fiscal burden was about €32.2 million and was projected to grow by 2030. Healthcare accounted for most of the total. The estimates provide a planning baseline and depend on modeling assumptions, including projected spending. 

"Skill-guided agentic reasoning enables longitudinal synthesis of myeloma records at expert-level concordance"

Source

Moll, J., Lübberstedt, J., Nuernbergk, C. et al. Skill-guided agentic reasoning enables longitudinal synthesis of myeloma records at expert-level concordance. npj Precis. Onc. 10, 389 (2026). https://doi.org/10.1038/s41698-026-01733-2 October 14, 2026. 

Overview

Researchers evaluated an AI system's ability to synthesize complex, long-term myeloma records against expert-adjudicated answers and other AI approaches. The skill-guided system reached 80.1% agreement and performed particularly well on long records. However, a greater share of its errors was clinically significant than expert disagreements, underscoring the need for further evaluation and human oversight before clinical reliance. 

"Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence"

Source

Mehmet Kanbay, Sidar Copur, Ibrahim Gulmaliyev, Can C Süsal, Caner Süsal, Adrian Covic, Mahmut Altindal, Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence, Nephrology Dialysis Transplantation, 2026;, gfag238, https://doi.org/10.1093/ndt/gfag238 October 15, 2026. 

Overview

This narrative review examines why anti-CD38 antibodies used in myeloma might also help selected immune-mediated kidney diseases and kidney-transplant complications. It summarizes how these medicines affect antibody-producing and other immune cells, alongside emerging clinical evidence. The purpose is to assess disease-specific opportunities and limitations, rather than establish routine treatment across kidney disorders. 

"The prognostic impact of CDH1 and MEG3 methylation status in multiple myeloma"

Source

Yamashita, S., Tachita, T., Kamata, K. et al. The prognostic impact of CDH1 and MEG3 methylation status in multiple myeloma. Int J Hematol (2026). https://doi.org/10.1007/s12185-026-04298-9 October 15, 2026. 

Overview

Researchers examined chemical modifications regulating CDH1 and MEG3 in bone marrow samples from 57 newly diagnosed patients. CDH1 promoter methylation and lack of MEG3 methylation showed possible associations with poorer outcomes, including survival trends. The small exploratory study investigates potential prognostic markers, but these findings are not yet validated for routine risk assessment. 

"Exploratory Identification of Potential Serum Biomarkers Associated with Relapse in Multiple Myeloma"

Source

Chantkran, W., Laoruangroj, C., Roytrakul, S., Nathalang, O., Arnutti, P ., Chaisakul, J., & Apipongrat, D. (2026). Exploratory Identification of Potential Serum Biomarkers Associated with Relapse in Multiple Myeloma. Diseases, 14(10), 380. https://doi.org/10.3390/diseases14100380 October 15, 2026. 

Overview

Researchers compared blood proteins during deep response and at relapse to identify candidate monitoring markers. Follow-up testing in paired samples from 40 patients found higher circulating TNFRSF8, also called CD30, at relapse, while PTBP2 did not change significantly. The source of the increase and its ability to detect or predict relapse remain uncertain and require prospective validation. 

"Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma"

Source

Miranda H. Meeuwsen, Anne K. Wouters, Johannes C. Wellershoff, Tassilo L. A. Wachsmann, Dennis F . G. Remst, Renate S. Hagedoorn, Michel G. D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Els P . van Hees, Masashi Matsuda, Fumihiko Ishikawa, Peter A. van Veelen, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk; Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma. Blood 2026; 148 (16): 1998-2012. doi: https://doi.org/10.1182/blood.2025032234 October 15, 2026. 

Overview

This preclinical study explored engineered T-cell receptors that recognize fragments of IgG or IgA proteins displayed by myeloma cells. The engineered cells killed patient-derived myeloma cells and eliminated tumors in mouse models, while also affecting normal B cells of the matching antibody type. The approach offers potential new targets but still needs clinical safety and effectiveness testing. 

"TCR T cells targeting IgA-and IgG-expressing multiple myeloma"

Source

Karolos Douvlataniotis, Aleksei Titov, Julia Zeun, Merve Bilici, Heyilimu Palashati, Waywen Loh, Even Holth Rustad, Weiwen Yang, Trung The Tran, Fridtjof Lund-Johansen, Ravi Chand Bollineni, Jessica D. Kepple, Luis P . Huth, Ludvig A. Munthe, Thorstein Boxaspen, Fredrik Schjesvold, Anders Waage, Dimitrios L. Wagner, Katherine R. Bull, Joanna Hester, Fadi Issa, Eirini Giannakopoulou, Johanna Olweus; TCR T cells targeting IgA-and IgG-expressing multiple myeloma. Blood 2026; 148 (16): 1984-1997. doi: https://doi.org/10.1182/blood.2025031897 October 15, 2026. 

Overview

Researchers developed T cells that recognize fragments of IgA or IgG presented by a specific HLA molecule. These cells selectively killed appropriately matched patient myeloma cells in laboratory tests, and IgA-directed cells eliminated tumors in mice. The study establishes a preclinical strategy whose patient eligibility depends on antibody type and HLA status; clinical benefit remains unproven. 

"Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma"

Source

Hitomi Hosoya, Arash Velayati, Danai Dima, Alexandria Jensen, Andrew J. Portuguese, Vanna Hovanky, Lekha Mikkilineni, Lauren C. Peres, Ariel Grajales-Cruz, Sylvester Homsy, Masooma Rana, Juancarlos Cancilla, Sunita Patil, Bita Sahaf, Theresa Latchford, Ciara Freeman, Brian Scott, Kun Wei Song, Omar Castaneda Puglianini, Humza Khan, Saurabh Dahiya, Frederick Locke, Crystal Mackall, David Miklos, Rahul Banerjee, Doris Hansen, Melissa Alsina, Surbhi Sidana; Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma. Blood 2026; 148 (16): 1961-1972. doi: https://doi.org/10.1182/blood.2025032844 October 15, 2026. 

Overview

Researchers examined whether CAR T-cell expansion could help identify patients at risk of delayed neurologic toxicity. Rapid, high expansion after cilta-cel was associated with these complications, and routine lymphocyte counts offered a practical surrogate in a larger cohort. The findings suggest a monitoring approach, but the proposed thresholds and preventive interventions require further validation. 

"Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH-MM-15 Study"

Source

T. Tsukamoto, Y . Shimura, S. Mizutani, et al., “Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH-MM-15 Study,” Cancer Science (2026): 1-14, https://doi.org/10.1111/cas.70564. October 15, 2026. 

Overview

This post hoc analysis investigated why patients with t(11;14) myeloma have differing outcomes. Among 482 assessed patients, the t(11;14)-positive group had fewer deep responses and distinctive survival and cell-marker patterns. Exploratory treatment associations varied by marker subgroup. The study challenges treating all t(11;14) cases as clinically uniform and calls for prospective validation of subgroup-specific approaches. 

"Frailty and quality of life in a real-world multiple myeloma population"

Source

Rydahl KFK, Möller S, Horsbøl TA, Høyer BB, Jensen BA, Helleberg C, et al. Frailty and quality of life in a real-world multiple myeloma population. Br J Haematol. 2026; 00: 1-12. https://doi.org/10.1111/bjh.70870 October 15, 2026. 

Overview

Researchers followed quality of life in 681 Danish patients to understand how frailty shapes experiences outside clinical trials. Frail patients started with poorer functioning and more fatigue. Some symptoms improved in newly diagnosed disease, while frail patients with relapsed disease experienced worsening pain and physical function. The findings support tailoring supportive care to frailty and disease setting. 

"Frailty score, sarcopenia, and myosteatosis: Stratifying risk and outcomes in non-transplant eligible patients with multiple myeloma treated with daratumumab-based dose-adjusted combination therapies"

Source

Terlizzi S, Falcone T, Frittoli B, Ribolla R, Crippa C, Ferrari S, Bianchetti N, Bottelli C, Vietti E, Avenoso D, Ravanelli M, Grazioli L, Tucci A, Belotti A. Frailty score, sarcopenia, and myosteatosis: Stratifying risk and outcomes in non-transplant eligible patients with multiple myeloma treated with daratumumab-based dose-adjusted combination therapies. J Geriatr Oncol. 2026 Oct 15;18(1):104640. doi: 10.1016/j.jgo.2026.104640. Epub ahead of print. 

Overview

Researchers reviewed 94 older, transplant-ineligible patients receiving dose-adjusted daratumumab combinations to compare the prognostic value of frailty, low muscle mass, and fat within muscle. Greater muscle fat was associated with poorer survival, while frailty and low muscle mass alone showed no statistically conclusive association. The findings support further study of muscle quality alongside standard assessments. 

"Patient-reported outcomes and skeletal symptoms in multiple myeloma stratified by proteasome inhibitor-based therapy: a prospective interdisciplinary cohort study"

Source

Maier, J.P ., Pietsch, C., Schmal, H. et al. Patient-reported outcomes and skeletal symptoms in multiple myeloma stratified by proteasome inhibitor-based therapy: a prospective interdisciplinary cohort study. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-17177-7 October 15, 2026. 

Overview

This prospective observational study compared symptoms and quality of life by current use of proteasome inhibitor therapy in 209 patients. After adjustment, researchers found no measurable differences in overall quality of life, bone pain, or existing bone lesions. The purpose was to explore whether proposed bone effects appear in routine care; treatment selection and limited follow-up prevent firm causal conclusions. 

"Identification of Macrophage Polarization-Related Biomarkers in Multiple Myeloma Using Integrated Bioinformatics"

Source

Wang, R., Zhang, J., Qi, J., Jiang, Y ., Wang, N., Huang, J., Tang, S., Wei, Y ., Xiang, Y ., He, H., Huang, L., Wei, Z. Identification of Macrophage Polarization-Related Biomarkers in Multiple Myeloma Using Integrated Bioinformatics. J. Vis. Exp. (236), e72728, doi:10.3791/72728 (2026). October 16, 2026. 

Overview

Researchers analyzed gene-expression datasets to identify macrophage-related markers associated with myeloma outcomes. They developed an eight-gene risk signature linked to survival, immune-cell patterns, and predicted drug sensitivity. The study offers candidate biomarkers and biological leads, but performance in research datasets does not establish that using the model improves treatment decisions or patient outcomes. 

"Association between blood urea nitrogen and prognosis in critical patients with multiple myeloma: a retrospective cohort study"

Source

Ding, H., Zou, X. Association between blood urea nitrogen and prognosis in critical patients with multiple myeloma: a retrospective cohort study. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-17200-x October 16, 2026. 

Overview

Researchers used intensive-care records to assess whether blood urea nitrogen levels at admission were associated with mortality in critically ill patients with myeloma. Higher levels were linked to greater short- and longer-term mortality after adjustment. The findings suggest a readily available risk marker, but do not show that lowering this laboratory value itself improves survival. 

"Circulating tumor plasma cells correlate with tumor burden and routine laboratory markers in newly diagnosed multiple myeloma: A retrospective single-center study"

Source

Du, X., Hu, D., Fu, W., Hu, H., Chen, W., Xu, X., Li, Y ., Tang, H., & Zhang, M. (2026). Circulating tumor plasma cells correlate with tumor burden and routine laboratory markers in newly diagnosed multiple myeloma: A retrospective single-center study. Medicine, 105(42), e51073. https://doi.org/10.1097/MD.0000000000051073 October 16, 2026. 

Overview

Researchers examined whether myeloma cells circulating in blood could reflect disease burden in newly diagnosed patients. In a small retrospective cohort, higher cell levels were associated with more marrow involvement, lower hemoglobin and albumin, and higher beta-2-microglobulin. The findings support further evaluation as an additional baseline assessment, but the study did not establish an ability to predict survival. 

"Mast cells may promote myeloma engraftment in the NSG-hIL6 patient derived xenograft model"

Source

Hasanali, Z.S., Garfall, A.L., Vogl, D.T. et al. Mast cells may promote myeloma engraftment in the NSG-hIL6 patient derived xenograft model. Sci Rep (2026). https://doi.org/10.1038/s41598-026-75919-w October 16, 2026. 

Overview

Researchers used patient-derived mouse models and laboratory cultures to explore whether mast cells help myeloma establish and survive in bone marrow. Mast cells were associated with faster and greater tumor engraftment, and a combination of their secreted factors improved myeloma-cell survival in culture. The work supports studying the marrow environment as a potential source of future treatment targets. 

"Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma"

Source

Dimopoulos, M.A., Hungria, V ., Meng, H. et al. Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J. 16, 184 (2026). https://doi.org/10.1038/s41408-026-01646-0 October 17, 2026. 

Overview

This research letter reports the final DREAMM-3 comparison of belantamab mafodotin alone with pomalidomide plus dexamethasone. Some responses lasted longer with belantamab, but the trial had not met its primary goal of superior progression-free survival, and the final descriptive analysis did not establish a survival advantage. Eye toxicity remained an important treatment burden requiring monitoring and dose adjustment. 

"Genetic similarity, Duffy-null genotype, and autologous transplant in multiple myeloma: Disparities in depth of response but not survival"

Source

Ayo S. Falade, Hongwei Tang, Michael Howe, Mahek Bai, Suganti Shivaram, Stacey Lehman, Huihuang Yan, Yan Asmann, Shaji Kumar, Vincent Rajkumar, Rahma Warsame, Megan Weivoda, Sikander Ailawahdhi, Linda Baughn, Joselle M. Cook; Abstract B064: Genetic similarity, Duffy-null genotype, and autologous transplant in multiple myeloma: Disparities in depth of response but not survival. Cancer Epidemiol Biomarkers Prev 1 October 2026; 35 (10_Supplement): B064. https://doi.org/10.1158/1538-7755.DISP26-B064 

Overview

Researchers examined whether genetic ancestry and the Duffy-null genotype were associated with response, survival, or transplant outcomes in a diverse cohort of 279 patients. Duffy-null status was linked to lower odds of a deep response, but neither genotype nor ancestry independently predicted survival. Strong overlap between ancestry and genotype limits causal interpretation, and larger studies are needed. 

"Sustained improvements in overall and myeloma-specific survival among patients with early-onset multiple myeloma: A population-based SEER analysis, 2000-2022"

Source

Philip Obiri Ankomah, Enoch Enninful, Penias Tembo, Birgit Abugrey, Isaac Obeng-Gyasi, Susan Onumanyiwa Nyanteh; Abstract B077: Sustained improvements in overall and myeloma-specific survival among patients with early-onset multiple myeloma: A population-based SEER analysis, 2000-2022. Cancer Epidemiol Biomarkers Prev 1 October 2026; 35 (10_Supplement): B077. https://doi.org/10.1158/1538-7755.DISP26-B077 

Overview

This SEER analysis examined whether survival improved over time among 2,610 people with early-onset myeloma diagnosed from 2000 through 2022. Later diagnosis years were associated with lower overall and myeloma-specific mortality. Improvements did not differ significantly across racial and ethnic groups. The findings document population trends but cannot attribute gains to particular treatments. 

"Improving access and affordability in multiple myeloma care: Patient and provider perspectives"

Source

Meera Muthukrishnan, Shelbie Fishman, Ravi Vij, Michael Slade, Dionne Stalling, Aimee S. James, Mengmeng Ji, Mark Fiala, Su-Hsin Chang; Abstract A091: Improving access and affordability in multiple myeloma care: Patient and provider perspectives. Cancer Epidemiol Biomarkers Prev 1 October 2026; 35 (10_Supplement): A091. https://doi.org/10.1158/1538-7755.DISP26-A091 

Overview

Researchers interviewed patients, providers, and staff to identify barriers to affordable, accessible myeloma care and possible solutions. Transportation, caregiver availability, insurance changes, and treatment costs were recurring concerns. Participants called for earlier needs assessment and clearer resource navigation, while staff shortages limited social-work support. The qualitative findings aim to guide service improvements, especially for underserved patients. 

"Sociodemographic bias in large language model-generated clinical recommendations for multiple myeloma: A systematic algorithmic audit"

Source

Shakira J. Grant; Abstract A156: Sociodemographic bias in large language model-generated clinical recommendations for multiple myeloma: A systematic algorithmic audit. Cancer Epidemiol Biomarkers Prev 1 October 2026; 35 (10_Supplement): A156. https://doi.org/10.1158/1538-7755.DISP26-A156 

Overview

This abstract outlines the need to examine whether AI-generated myeloma treatment recommendations vary unfairly by patients' social or demographic characteristics. It describes existing care disparities and evidence of bias in AI tools used in other settings. The supplied excerpt provides background and the research problem, but no audit methods or results specific to myeloma. 

"A comparison of the association of three neighborhood-level socioeconomic indicators on diagnostic disease state of plasma cell dyscrasia"

Source

Zachary H. Fusfeld, Tara Rakiewicz, Adam Binder, Terry Hyslop; Abstract B110: A comparison of the association of three neighborhood-level socioeconomic indicators on diagnostic disease state of plasma cell dyscrasia. Cancer Epidemiol Biomarkers Prev 1 October 2026; 35 (10_Supplement): B110. https://doi.org/10.1158/1538-7755.DISP26-B110 

Overview

Researchers compared three neighborhood-level socioeconomic measures to assess how disadvantage relates to whether a plasma cell disorder is first identified as MGUS, smoldering myeloma, or active myeloma. Among 6,831 patients, two deprivation measures were associated with a more advanced diagnostic category, while the Social Vulnerability Index was not. The findings may inform research into inequities in detection and access. 

"Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma"

Source

Garikipati, N. A., Guntupalli, S. V ., Korrapati, R. K., Mikkilineni, J., Kondepudi, S., Shaik, B., Gurugubelli, S., & Nimmagadda, R. (2026). Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma. Annals of African Medicine https://doi.org/10.4103/aam.aam_391_25 October 19, 2026. 

Overview

This review summarizes evidence for talquetamab in heavily pretreated relapsed or refractory myeloma, including after earlier T-cell therapies. It discusses response rates, adverse effects, resistance to other immune treatments, and ongoing combination approaches. The purpose is to explain talquetamab's potential place in treatment, rather than report a new comparative clinical trial. 

"CD4+GM-CSF+ T Cells in Multiple Myeloma Patients"

Source

Batorov, E., Tyrinova, T., Leplina, O., Pronkina, N., Aristova, T., Denisova, V ., Batorova, D., Sizikova, S., Ushakova, G., & Chernykh, E. (2026). CD4+GM-CSF+ T Cells in Multiple Myeloma Patients. Lymphatics, 4(4), 55. https://doi.org/10.3390/lymphatics4040055 October 19, 2026. 

Overview

Researchers studied a subset of helper T cells producing GM-CSF to clarify whether they contribute to immune suppression in myeloma. Among 54 patients and 10 healthy donors, these cells were more frequent in patients, but did not correlate with suppressive myeloid-cell counts. The experiments did not support the proposed tumor-promoting role, helping refine understanding of the immune environment. 

"Infectious Complications and Toxicities of the Teclistamab Plus Daratumumab Combination in Relapsed or Refractory Multiple Myeloma: A Disproportionality and Drug-Interaction Analysis of the FDA Adverse Event Reporting System"

Source

Awadallah, C., Irfan, S., Abdallah, A.-O., & Bilal Abid, M. (2026). Infectious Complications and Toxicities of the Teclistamab Plus Daratumumab Combination in Relapsed or Refractory Multiple Myeloma: A Disproportionality and Drug-Interaction Analysis of the FDA Adverse Event Reporting System. Cancers, 18(20), 3388. https://doi.org/10.3390/cancers18203388 October 19, 2026. 

Overview

Researchers analyzed adverse-event reports to explore whether teclistamab plus daratumumab had higher-than-expected reporting of infections and other toxicities. Respiratory infection signals were observed, but some weakened with alternative analyses. The purpose is to identify safety questions for further study; spontaneous reports cannot establish infection rates, prove a drug interaction, or show that less-reported events are prevented. 

"Challenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM)"

Source

Strelau, M., Gal, G. L., McCurdy, A., Shivakumar, S., Wootten, J. C., Abouzeenni, M., Phua, C. W., Lam, S., Lazo-Langner, A., Abouzeenni, M. Y ., & Louzada, M. (2026). Challenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM). Current Oncology, 33(10), 633. https://doi.org/10.3390/curroncol33100633 October 19, 2026. 

Overview

This pilot randomized trial assessed whether a larger comparison of rivaroxaban and aspirin for clot prevention during lenalidomide-based therapy would be feasible. Recruitment fell short of prespecified goals during COVID-19 restrictions. Two clotting and two bleeding events occurred, all with aspirin, but the 55-patient pilot was too small to establish comparative safety or effectiveness. 

"Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy"

Source

Magrangeas, F ., Cherkaoui, M., Bessonneau-Gaborit, V . et al. Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy. Nat Med (2026). https://doi.org/10.1038/s41591-026-04692-0 October 19, 2026. 

Overview

Researchers analyzed tumor genetics, gene activity, and DNA regulation in 423 newly diagnosed patients to identify predictors of MRD response after four-drug induction. Molecular subgroups differed in MRD-negative rates, and an integrated model improved prediction over some simpler models. The findings may inform future response-adapted care but do not establish that changing treatment using the model improves outcomes. 

"Patients' , family caregivers' , and professionals' perspectives on the quality of cancer drug injections at home: A qualitative and comparative study in France"

Source

Bénédicte Mittaine-Marzac, Rakiba Belkhir, Katayoun Jondeau, Laurent Garderet, Laurent Frenzel, Sarah Ivanoff, Arsène Zogo, Liette Lapointe, Joël Ankri, Philippe Aegerter, Matthieu De Stampa, Patients' , family caregivers' , and professionals' perspectives on the quality of cancer drug injections at home: A qualitative and comparative study in France, Geriatric Nursing, Volume 73, 2026, 104286, ISSN 0197-4572, https://doi.org/10.1016/j.gerinurse.2026.104286. October 2026. 

Overview

This qualitative study explored patients', caregivers', and professionals' experiences with myeloma drug injections at home compared with day-hospital care. Across 35 interviews, home care offered convenience but required complex coordination and strong hospital-community collaboration. The purpose was to identify service needs and suitable patient profiles, rather than demonstrate equivalent safety or cancer outcomes. 

"Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2-AMPK-PGC1α Metabolic Axis"

Source

F . Peng, Y . Gao, Z. Zhang, et al., “Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2-AMPK-PGC1α Metabolic Axis,” Journal of Clinical Laboratory Analysis (2026): e70384, https://doi.org/10.1002/jcla.70384. October 20, 2026. 

Overview

Researchers tested how shikonin, a natural compound, affects myeloma-cell metabolism. In laboratory experiments, it lowered PKM2 expression, disrupted glucose processing, increased metabolic stress, and triggered cell death. The findings identify a possible metabolic treatment strategy, but do not establish safe dosing, clinical effectiveness, or a role for shikonin in patient care. 

"Real-world analysis of infusion-related reactions in patients receiving subcutaneous daratumumab in Nova Scotia, Canada"

Source

Jang HW (Sam), Godin J, Rolle M, De la Torre A, White D, Minard LV . Real-world analysis of infusion-related reactions in patients receiving subcutaneous daratumumab in Nova Scotia, Canada. Journal of Oncology Pharmacy Practice. 2026;0(0). doi:10.1177/10781552261500471 October 21, 2026. 

Overview

Researchers reviewed first-cycle reactions to subcutaneous daratumumab in 140 patients with myeloma or AL amyloidosis to assess monitoring needs. Reactions were uncommon and mostly mild, although one severe oxygen-related event occurred and some reactions began after an hour. The findings informed a shorter local observation policy, but the retrospective study does not establish a universal observation period or optimal steroid dose. 

"Extramedullary Disease and Prolonged Hematotoxicity After Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Real-World Evidence Synthesis"

Source

Soomro, M. A., Khaliq, A., Bilal Abid, M., Paul, B., Atrash, S., Shaikh, H., Mazloom, A., Alkharabsheh, O., Mewawalla, P ., Shah, M. R., Khan, A. M., Mahmoudjafari, Z., Mushtaq, M. U., Kort, J., Habib, A., & Abdallah, A.-O. (2026). Extramedullary Disease and Prolonged Hematotoxicity After Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Real-World Evidence Synthesis. Current Oncology, 33(11), 642. https://doi.org/10.3390/curroncol33110642 October 21, 2026. 

Overview

This evidence synthesis reviewed real-world ide-cel studies to clarify outcomes in extramedullary disease and the burden of prolonged low blood counts. Independent cohorts consistently associated extramedullary disease with shorter progression-free survival, while severe cytopenias remained common months after treatment. The findings support risk assessment and recovery planning, with overlapping datasets and differing study methods limiting pooled comparisons. 

"Exploring Non-Covalent Pin1-PROTACs Insights Into Degradation Efficiency in Multiple Myeloma Cell Line"

Source

L. Meneghelli, S. Davidson, J. Choi, et al. “Exploring Non-Covalent Pin1-PROTACs Insights Into Degradation Efficiency in Multiple Myeloma Cell Line.” Chemistry & Biodiversity 23, no. 10 (2026): e71850. https://doi.org/10.1002/cbdv.71850 October 21, 2026. 

Overview

Researchers designed 12 experimental compounds to promote degradation of Pin1, a protein linked to myeloma growth and resistance, without permanently binding the target. The new compounds showed little degradation, while an existing covalent comparator worked more strongly. The study identifies obstacles in drug design and informs future development rather than demonstrating an effective new treatment. 

"A role for eIF5A in translational control of stress-inducible proteins in multiple myeloma cell lines"

Source

Both, D., Derks, I.A.M., Vanleyssem, R., Leclercq, M., El Hachem, N., Close, P ., Eldering, E. and Haselager, M. V . (2026), A role for eIF5A in translational control of stress-inducible proteins in multiple myeloma cell lines. Mol Oncol. https://doi.org/10.1002/1878-0261.70328 October 21, 2026. 

Overview

This cell-line study investigated how eIF5A, a protein involved in making other proteins, affects myeloma's response to cellular stress. Removing eIF5A altered production of selected stress-response proteins and reduced sensitivity to thapsigargin, but effects differed with other stress-inducing drugs. The purpose is to clarify resistance mechanisms and potential research targets, without establishing a clinical treatment strategy. 

"Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma"

Source

Sham Mailankody, Sneha Mitra, Kevin Herrera, Bachisio Ziccheddu, Briana Cadzin, Ozgur Can Eren, Tasmin Farzana, Tahmin Ullah, Jonathan Landa, Andriy Derkach, Jagrutiben Chaudhari, Devin P . McAvoy, Kinga Hosszu, Gunjan L. Shah, Heather Landau, Francesco Maura, Ahmet Dogan, Sergio Giralt, Xiuyan Wang, Michel Sadelain, Eric L. Smith, Renier J. Brentjens, Christina Leslie, Saad Z. Usmani, Karlo Perica; Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma. Blood 2026; 148 (17): 2121-2131. doi: https://doi.org/10.1182/blood.2025032122 October 22, 2026. 

Overview

This phase 1 trial tested the safety of simultaneously administering separate BCMA- and GPRC5D-directed CAR T-cell products. Nine patients received both products, with a 78% response rate, but an inflammatory complication occurred and biological analyses suggested competition between CAR populations and persistent antigen-loss resistance. The small study supports further optimization and cannot establish superiority over single-target therapy. 

"Plasma Cell Leukemia: Experience from a Tertiary Cancer Care Center in India"

Source

Narayanan, G., Kumar, B.S., Thambi, S.M. et al. Plasma Cell Leukemia: Experience from a Tertiary Cancer Care Center in India. Indian J Hematol Blood Transfus (2026). https://doi.org/10.1007/s12288-026-02585-3 October 22, 2026. 

Overview

Researchers reviewed 47 primary plasma cell leukemia cases at an Indian cancer center to describe presentation and outcomes in a resource-limited setting. Survival was short, and only two patients underwent transplantation. The report highlights aggressive disease and limited treatment access, supporting further study of modern combination approaches while offering no randomized comparison of treatment strategies. 

"Multiple myeloma in the Netherlands: 35-year trends in incidence and survival"

Source

Klomberg, K.M., Roeloffzen, W.W.H., Nijland, M. et al. Multiple myeloma in the Netherlands: 35-year trends in incidence and survival. Leukemia (2026). https://doi.org/10.1038/s41375-026-03156-1 October 22, 2026. 

Overview

This research letter uses a nationwide registry to examine myeloma incidence and survival in the Netherlands from 1989 through 2022. Age-standardized incidence remained stable, while survival improved substantially among treated patients across age groups. Outcomes remained poorer above age 70. The findings describe progress across treatment eras, but limited treatment details prevent attributing gains to individual therapies. 

"Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care"

Source

Hansen, D.K., Zanwar, S., Peres, L.C. et al. Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01649-x October 22, 2026. 

Overview

Researchers studied 598 cilta-cel recipients to identify high-risk features associated with earlier or later treatment failure. Extramedullary disease, poorer physical performance, and prior BCMA therapy were associated with failure within six months, while early frontline relapse and high-risk genetics were associated with later failure. The findings may inform counseling and follow-up, but risk-based treatment changes need prospective evaluation. 

"Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma"

Source

Jagannath S, Martin TG, Lin Y , Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F , Montes de Oca R, Plaks V , Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma. Future Oncol. 2026 Oct 12:1-12. doi: 10.1080/14796694.2026.2720305. 

Overview

This plain-language article explains long-term CARTITUDE-1 results after a single cilta-cel infusion in 97 heavily pretreated patients. At least five years later, 32 participants remained alive without progression or additional myeloma treatment, and median overall survival was 60.7 months. The purpose is to communicate evidence of durable remission in some patients, without establishing that the treatment cures myeloma. 

"Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial"

Source

He H, Shang J, Wang Y , Xia Z, Zhu F , Yang Y , Fang B, Chen W, Chen B, Cai Z, Zhou H, Li Y , Liu H, Chen L, Liu Y , Huang Z, Zeng P , Jin J, Li Y , Mi J, Zhou Z, Gao S, Xi Y , Wang Q, Chang C, Du X, Huang SY , Wang HY , Ko PS, Shao Z, Luo J, Wang S, Huang J, Dai M, Yang T, Zhan R, Liang B, Wang MC, Wu S, Zhong L, Wei Y , Wang H, Wu H, Li J, Teng CL, Meng Y , Wu M, Yang P , Chen X, Zhu AX, Fu W, Wu D, Fu C. Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial. Lancet Haematol. 2026 Oct;13(10):e722-e736. doi: 10.1016/S2352-3026(26)00223-1. 

Overview

This randomized phase 3 trial in China tested whether adding felzartamab to lenalidomide and dexamethasone improved disease control in relapsed or refractory myeloma. Median progression-free survival improved from 10.4 to 18.9 months, but severe blood-count abnormalities, infections, and treatment-related deaths were more frequent with the combination. Participants were not lenalidomide-refractory, which matters when interpreting applicability. 

"MGUS in Black individuals in Soweto, South Africa screened by mass spectrometry: results of the PROMISE South Africa study"

Source

Lee DJ, Chen WC, Bertamini L, El-Khoury H, Allam S, Fleming G, Alberge JB, Perry J, Davis MI, Lightbody E, Goqwana LN, Philip V , Pentz BRad A, Dip Tchg TH, Redd R, Sakrikar D, Barnidge D, Perkins MC, Harding S, Colchie J, Karlson EW, Rebbeck TR, Getz G, Joffe M, Ghobrial IM, Marinac CR. MGUS in Black individuals in Soweto, South Africa screened by mass spectrometry: results of the PROMISE South Africa study. EClinicalMedicine. 2026 Oct 2;100:104208. doi: 10.1016/j.eclinm.2026.104208. 

Overview

The PROMISE South Africa study screened 2,004 Black adults in Soweto using mass spectrometry to estimate MGUS prevalence and explore associated exposures. Heavy-chain MGUS was detected in 12% and light-chain MGUS in 3%. HIV and smoking were associated with higher prevalence. The single-visit design cannot establish causes or progression risk and supports further longitudinal research. 

"Elevated serum soluble PD-L1 is associated with adverse outcomes after autologous stem cell transplantation in transplant-eligible multiple myeloma patients"

Source

Naguib MG, Fathy M, Mohamed HS, Moussa MM, Eid IAM. Elevated serum soluble PD-L1 is associated with adverse outcomes after autologous stem cell transplantation in transplant-eligible multiple myeloma patients. Egypt J Immunol. 2026 Oct;33(4):131-143. doi: 10.55133/eji.330412. October 2026. 

Overview

Researchers measured soluble PD-L1 before and six months after autologous transplantation in 40 patients to assess its relationship with outcomes. Higher levels were associated with poorer survival and relapse, and higher post-transplant levels with graft failure. The study explores a potential risk marker, but its small size, short follow-up, and multiple unadjusted comparisons make the findings preliminary. 

"CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling"

Source

Angélique Bruyer, Nicolas Robert, Jules Varbedian, Elvira Garcia De Paco, Lauryn Jaffory, Stéphanie Boireau, Christophe Hirtz, Jérôme Vialaret, Pierre Martineau, Bruno Robert, Guilhem Requirand, Guillaume Cartron, Laure Vincent, Charles Herbaux, Jérôme Moreaux, Caroline Bret, CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling, Translational Oncology, Volume 72, 2026, 103000, ISSN 1936-5233, https://doi.org/10.1016/j.tranon.2026.103000. October 2026. 

Overview

Researchers investigated whether CD200, a protein already linked to immune suppression, also directly promotes myeloma-cell growth. Experimental findings showed growth effects dependent on interaction with the IGF-1 receptor, and high expression of both proteins was associated with poorer patient outcomes. The work suggests a potential combined treatment target, with therapeutic benefit requiring further investigation. 

"Fresh (Non-cryopreserved) autologous stem cell transplantation in multiple myeloma: Faster engraftment and reduced hospitalization"

Source

Merve Kakci, Osman Can Öztürk, Ömer Şeker, Semih Basci, Hikmetullah Batgi, Sinem Namdaroğlu, Fresh (Non-cryopreserved) autologous stem cell transplantation in multiple myeloma: Faster engraftment and reduced hospitalization, Hematology, Transfusion and Cell Therapy, Volume 48, Issue 4, 2026, 106513, ISSN 2531-1379, https://doi.org/10.1016/j.htct.2026.106513. October-December 2026. 

Overview

Researchers reviewed 40 patients who received fresh rather than frozen stem cells for autologous transplantation to assess feasibility, recovery, and toxicity. All achieved engraftment, and no infusion-related adverse events were observed. The approach avoided the freezing preservative and related resource use, but the uncontrolled study cannot establish faster recovery, lower costs, or superiority over standard cryopreserved transplantation. 

"Innovations and Inequalities: The Challenge of Access in Multiple Myeloma Management in Brazil"

Source

Glaciano Nogueira Ribeiro, Edvan de Queiroz Crusoé, Angelo Maiolino, Vania de T. Moraes Hungria, Innovations and Inequalities: The Challenge of Access in Multiple Myeloma Management in Brazil, Hematology, Transfusion and Cell Therapy, Volume 48, Issue 4, 2026, 107414, ISSN 2531-1379, https://doi.org/10.1016/j.htct.2026.107414. October-December 2026. 

Overview

This commentary examines gaps between advances in myeloma treatment and access within Brazil's public healthcare system. Drawing on registry and published data, the authors describe survival disparities, delayed availability of newer medicines, and barriers to essential diagnostic tests. Its purpose is to argue for more equitable implementation of effective care, including supportive services, rather than report a new randomized study. 

"Radio-Biological Enhancement of an Interleukin-6 Receptor Antibody by the β-Particle-Emitting Radionuclide Iodine-131 in Multiple Myeloma"

Source

Goto H, Ueda Y , Takano M, Sungwan P , Shiraishi Y , Hasegawa K, Okada S. Radio-Biological Enhancement of an Interleukin-6 Receptor Antibody by the β-Particle-Emitting Radionuclide Iodine-131 in Multiple Myeloma. Biol Pharm Bull. 2026;49(10):1667-1675. doi: 10.1248/bpb.b26-00269. 

Overview

Researchers tested whether attaching radioactive iodine-131 to tocilizumab could strengthen its antimyeloma activity beyond blocking the interleukin-6 receptor alone. The labeled antibody inhibited myeloma-cell growth in laboratory experiments and suppressed tumors in mice, including models not responsive to interleukin-6 signaling. The findings support further preclinical development; safety and effectiveness in patients remain unestablished.